Monte Rosa Therapeutics (GLUE) Cash & Equivalents Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 23.81% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 15.53% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 90.42% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 17.50% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -4.13% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 71.81% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | 763.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 763.48% |
| Dec 31, 2025 | -65.91% |
| Sep 30, 2025 | 219.83% |
| Jun 30, 2025 | 176.40% |
| Mar 31, 2025 | -21.27% |
| Dec 31, 2024 | 197.39% |
| Sep 30, 2024 | 112.64% |
| Jun 30, 2024 | 131.46% |
| Mar 31, 2024 | 92.40% |
| Dec 31, 2023 | 133.28% |
| Sep 30, 2023 | -47.46% |
| Jun 30, 2023 | -54.64% |
| Mar 31, 2023 | -62.51% |
| Dec 31, 2022 | -84.13% |
| Sep 30, 2022 | -69.38% |
| Jun 30, 2022 | -70.97% |
| Mar 31, 2022 | -17.89% |
| Dec 31, 2021 | 766.72% |
| Sep 30, 2021 | 610.30% |
| Jun 30, 2021 | 2,710.17% |